Evidence map›Paper›PMID 31871080›Full record

ArticleAntimicrobial agents and chemotherapy2020

Clinical Mutations That Partially Activate the Stringent Response Confer Multidrug Tolerance in

Duncan Bryson, Andrew G Hettle, Alisdair B Boraston, Joanne K Hobbs

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Adaptive laboratory evolution ofFrontiers in microbiology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024
    Review
  14. Article
  15. ClinicalmSphere · 2023
    Article
  16. Review
  17. Article
  18. Antimicrobial Efficacy against Antibiotic-TolerantAntibiotics (Basel, Switzerland) · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Duncan BrysonDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
Andrew G HettleDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
Alisdair B BorastonDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
Joanne K HobbsDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada jhobbs@uvic.ca.ORCID 0000-0001-5239-8039
University of Victoria · CA

Funding

CIHR PJT 159786
6 · The paper itself

Abstract

Antibiotic tolerance is an underappreciated antibiotic escape strategy that is associated with recurrent and relapsing infections, as well as acting as a precursor to resistance. Tolerance describes the ability of a bacterial population to survive transient exposure to an otherwise lethal concentration of antibiotic without exhibiting an elevated MIC. It is detected in time-kill assays as a lower rate of killing than a susceptible strain and can be quantified by the metric minimum duration for killing (MDK). The molecular mechanisms behind tolerance are varied, but activation of the stringent response (SR) via gene knockouts and/or chemical induction has long been associated with tolerance. More recently, two Gram-positive clinical isolates from persistent bacteremias were found to bear mutations in the SR controller, Rel, that caused elevated levels of the alarmone (p)ppGpp. Here, we show that introduction of either of these mutations into

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialMicrobial Sensitivity TestsMutationStaphylococcus aureusAnti-Bacterial Agentsantibiotic toleranceminimum duration for killingStaphylococcus aureusstringent responsetime-kill curves

Identifiers

PMID31871080
PMCPMC7038295
OpenAlexW2998379654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.